Patent Assignment
Reel/Frame 038371/0471
Assignment of Assignor's Interest
Recorded: 2016-04-25
Pages: 10
Assignee
MERRIMACK PHARMACEUTICALS, INC.
ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE, MASSACHUSETTS, 02139
Covered Properties
(4)
Methods of Treating Patients Having Mutations in the Extracellular Domain of Epidermal Growth Factor Receptor (Egfr) with a Combination of Three Fully Human Monocolonal Anti-Egfr Antibodies
Application:
62/152,707 →
Methods of Treating Patients Having Mutations in the Extracellular Domain of Epidermal Growth Factor Receptor (Egfr) with a Combination of Three Fully Human Monoclonal Anti-Egfr Antibodies
Application:
62/244,991 →
Methods of Treating Patients Having Mutations in the Extracellular Domain of Epidermal Growth Factor Receptor (Egfr) with a Combination of Three Fully Human Monoclonal Anti-Egfr Antibodies
Application:
62/308,697 →
Methods of Treating Patients Having Mutations in the Extracellular Domain of Epidermal Growth Factor Receptor (Egfr) with a Combination of Three Fully Human Monoclonal Anti-Egfr Antibodies
Application:
62/323,475 →
Related Assignments
(4)
Other recorded transfers of the patents in this record — the chain of ownership.
Security Interest
Dec 28, 2015
From: MERRIMACK PHARMACEUTICALS, INC.
To: U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 037394/0285 →
Assignment of Assignor's Interest
Apr 25, 2016
From: KEARNS, JEFFREY D.; WOLF, BENI B.
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 038371/0286 →
Assignment of Assignor's Interest
Apr 25, 2016
From: NERING, RACHEL C.; WANG, HONGFANG
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 038371/0372 →
Release of Security Interest
Apr 14, 2017
From: U.S. BANK NATIONAL ASSOCIATION
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 042254/0349 →